Cargando…
CAR-T: What Is Next?
SIMPLE SUMMARY: In 2017, two chimeric antigen receptor-T (CAR-T) therapies were approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia. However, despite the breakthrough efficacy results, the safety of CAR-T treatment is still a concern for treating physicians and their...
Autores principales: | Chen, Yi-Ju, Abila, Bams, Mostafa Kamel, Yasser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913679/ https://www.ncbi.nlm.nih.gov/pubmed/36765623 http://dx.doi.org/10.3390/cancers15030663 |
Ejemplares similares
-
CAR-T Therapy, the End of a Chapter or the Beginning of a New One?
por: Mostafa Kamel, Yasser
Publicado: (2021) -
MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?
por: Britten, Oliver, et al.
Publicado: (2019) -
CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023) -
CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016) -
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
por: Moghanloo, Ehsan, et al.
Publicado: (2021)